Asset
BRINCIDOFOVIR
Emergent BioSolutions Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05935917 | phase1 | completed | 2023-05-30 | 2023-08-14 | Emergent BioSolutions | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 214460 | NDA | EMERGENT BIODEFENSE OPERATIONS LANSING LLC |
| NDA 214461 | NDA | EMERGENT BIODEFENSE OPERATIONS LANSING INC |
Marketed products (2)
- TEMBEXA
- TEMBEXA